Table 3 Outcome following induction therapy in pediatric acute myeloid leukemia cases.

Abbreviations: AML 2012, double induction regimen consisting of idarubicin (IDA) or mitoxantrone plus cytarabine based chemotherapy; KSBRM, idarubicin plus N4-behenoyl-1-β-D-arabinofuranosyl cytosine (BHAC) based chemotherapy; Responder, complete remission plus partial remission.

Blood Res 2018;53:25~34 https://doi.org/10.5045/br.2018.53.1.25